Vitaly Margulis

List of Publications by Citations

338 papers	10,504 citations	53 h-index	92 g-index
370 ext. papers	12,711 ext. citations	4.2 avg, IF	5.76 L-index

#	Paper	IF	Citations
338	Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer*, **2009**, 115, 1224-33	6.4	739
337	BAP1 loss defines a new class of renal cell carcinoma. *Nature Genetics*, **2012**, 44, 751-9	36.3	630
336	Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. *European Urology*, **2012**, 62, 100-14	10.2	276
335	Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. *Nature Genetics*, **2015**, 47, 13-21	36.3	247
334	Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. *Journal of Clinical Oncology*, **2009**, 27, 612-8	2.2	209
333	Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. *Cancer*, **2010**, 116, 3127-34	6.4	174
332	Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. *Journal of Urology*, **2009**, 182, 900-6	2.5	172
331	Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *Journal of Urology*, **2009**, 181, 2482-9	2.5	154
330	Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *European Urology*, **2012**, 61, 818-25	10.2	153
329	Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. *Journal of Urology*, **2010**, 184, 453-8	2.5	151
328	Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. *European Urology*, **2014**, 65, 210-7	10.2	150
327	Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. *Cancer*, **2010**, 116, 3378-88	6.4	150
326	A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. *Science Translational Medicine*, **2012**, 4, 137ra75	17.5	141
325	The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. *European Urology*, **2012**, 61, 245-53	10.2	135
324	Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. *European Urology*, **2010**, 57, 1072-9	10.2	133
323	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. *Cancer*, **2014**, 120, 1794-9	6.4	132
322	Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. *BJU International*, **2009**, 103, 307-11	5.6	131

321	Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. *Journal of Urology* , **2008**, 180, 94-8	2.5	131
320	Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. *European Urology*, **2009**, 56, 1-9	10.2	130
319	The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. *European Urology*, **2011**, 59, 912-8	10.2	126
318	The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed?. *European Urology*, **2009**, 56, 512-8	10.2	126
317	Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. *European Urology*, **2010**, 57, 575-81	10.2	125
316	Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. *Clinical Cancer Research*, **2006**, 12, 7369-73	12.9	124
315	Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. *Journal of the National Cancer Institute*, **2009**, 101, 114-9	9.7	119
314	Isotope Tracing of Human Clear Cell Renal Cell Carcinomas Demonstrates Suppressed Glucose Oxidation In Vivo. *Cell Metabolism*, **2018**, 28, 793-800.e2	24.6	118
313	Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. *Journal of Urology*, **2013**, 189, 1662-9	2.5	117
312	Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. *European Urology*, **2011**, 60, 776-83	10.2	106
311	Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. *BJU International*, **2013**, 112, 453-61	5.6	97
310	Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. *European Urology*, **2014**, 65, 650-8	10.2	94
309	Short-term efficacy of temperature-based radiofrequency ablation of small renal tumors. *Urology*, **2005**, 65, 877-81	1.6	86
308	Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. *BJU International*, **2010**, 105, 1672-7	5.6	84
307	Survivin: a promising biomarker for detection and prognosis of bladder cancer. *World Journal of Urology*, **2008**, 26, 59-65	4	81
306	Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma. *Cancer*, **2008**, 112, 1480-8	6.4	81
305	Perioperative outcomes following surgical resection of renal cell carcinoma with inferior vena cava thrombus extending above the hepatic veins: a contemporary multicenter experience. *European Urology*, **2014**, 66, 584-92	10.2	76
304	Predictors of oncological outcome after resection of locally recurrent renal cell carcinoma. *Journal of Urology*, **2009**, 181, 2044-51	2.5	75

303	Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. *European Urology*, **2012**, 62, 677-84	10.2	74
302	Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. *BJU International*, **2009**, 103, 302-6	5.6	73
301	Nomograms for bladder cancer. *European Urology*, **2008**, 54, 41-53	10.2	70
300	A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. *Nature Communications*, **2015**, 6, 8699	17.4	68
299	Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. *Clinical Cancer Research*, **2008**, 14, 3785-91	12.9	67
298	Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. *European Urology*, **2013**, 63, 1082-90	10.2	65
297	Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 252-8	2.8	65
296	Inventory of prostate cancer predictive tools. *Current Opinion in Urology*, **2008**, 18, 279-96	2.8	64
295	Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. *Urology*, **2009**, 73, 142-6	1.6	62
294	Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. *BJU International*, **2011**, 108, 1286-91	5.6	61
293	Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. *European Urology*, **2012**, 61, 1069-70	10.2	60
292	Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. *European Urology*, **2013**, 64, 465-71	10.2	59
291	BAP1 immunohistochemistry predicts outcomes in a multi-institutional cohort with clear cell renal cell carcinoma. *Journal of Urology*, **2014**, 191, 603-10	2.5	58
290	Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *European Urology*, **2013**, 63, 947-52	10.2	55
289	Metabolism of kidney cancer: from the lab to clinical practice. *European Urology*, **2013**, 63, 244-51	10.2	54
288	Conditional survival after radical nephroureterectomy for upper tract carcinoma. *European Urology*, **2015**, 67, 803-12	10.2	54
287	Lynch Syndrome: A Primer for Urologists and Panel Recommendations. *Journal of Urology*, **2015**, 194, 21-9	2.5	53
286	Acute histologic effects of temperature-based radiofrequency ablation on renal tumor pathologic interpretation. *Urology*, **2004**, 64, 660-3	1.6	53

285	Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?. *Urologic Oncology: Seminars and Original Investigations*, **2011**, 29, 716-23	2.8	50
284	New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. *BJU International*, **2008**, 101, 675-83	5.6	49
283	Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. *Journal of Urology*, **2007**, 178, 1878-82	2.5	49
282	Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system. *Cancer*, **2007**, 109, 2439-44	6.4	49
281	Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. *Urology*, **2009**, 74, 1070-4	1.6	48
280	Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort. *Journal of Urology*, **2014**, 192, 1050-6	2.5	47
279	Robot-Assisted Versus Open Simple Prostatectomy for Benign Prostatic Hyperplasia in Large Glands: A Propensity Score-Matched Comparison of Perioperative and Short-Term Outcomes. *Journal of Endourology*, **2017**, 31, 1164-1169	2.7	47
278	Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. *Cancer*, **2009**, 115, 2355-60	6.4	47
277	Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. *Cancer*, **2007**, 109, 2025-30	6.4	47
276	Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma. *BJU International*, **2007**, 100, 1235-9	5.6	47
275	Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. *International Journal of Urology*, **2012**, 19, 1060-6	2.3	46
274	Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. *European Urology*, **2011**, 59, 619-28	10.2	44
273	Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases. *International Journal of Radiation Oncology Biology Physics*, **2017**, 98, 91-100	4	42
272	Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. *Journal of Urology*, **2012**, 187, 845-51	2.5	42
271	Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. *Annals of Surgical Oncology*, **2012**, 19, 4337-44	3.1	42
270	Cytokine response to surgical stress: comparison of pure laparoscopic, hand-assisted laparoscopic, and open nephrectomy. *Journal of Endourology*, **2005**, 19, 1140-5	2.7	42
269	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. *BJU International*, **2018**, 121, 252-259	5.6	41
268	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. *Journal of Urology*, **2017**, 198, 1253-1262	2.5	41

267	Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma. *BJU International*, **2014**, 113, 668-73	5.6	40
266	Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. *Journal of Urology*, **2007**, 177, 1163-8	2.5	39
265	Impact of hospital case volume on testicular cancer outcomes and practice patterns. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 14.e7-14.e15	2.8	38
264	Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. *Urology*, **2013**, 81, 972-7	1.6	38
263	Predictive factors of recurrence and survival of upper tract urothelial carcinomas. *World Journal of Urology*, **2011**, 29, 495-501	4	38
262	Predicting survival after radical cystectomy for bladder cancer. *BJU International*, **2008**, 102, 15-22	5.6	38
261	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. *Journal of Urology*, **2020**, 203, 690-698	2.5	38
260	Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. *Clinical Genitourinary Cancer*, **2016**, 14, e25-36	3.3	34
259	Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. *Urology*, **2013**, 81, 581-6	1.6	34
258	Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 981-8	2.8	33
257	Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification. *European Urology*, **2012**, 62, 224-31	10.2	33
256	Upper tract urothelial carcinoma: impact of time to surgery. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 266-72	2.8	33
255	Oncologic outcomes of partial versus radical nephrectomy for unilateral Wilms tumor. *Pediatric Blood and Cancer*, **2012**, 58, 898-904	3	33
254	Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 2366-73	4	33
253	Laparoscopic and open retroperitoneal lymph-node dissection for clinical stage I nonseminomatous germ-cell testis tumors. *Journal of Endourology*, **2006**, 20, 627-31	2.7	32
252	A comparison of pediatric, adolescent, and adult testicular germ cell malignancy. *Pediatric Blood and Cancer*, **2014**, 61, 446-51	3	31
251	Surgical management of renal cell carcinoma. *Seminars in Interventional Radiology*, **2014**, 31, 27-32	1.6	31
250	Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU International*, **2011**, 108, E304-9	5.6	31

249	Retrograde renal cooling during radio frequency ablation to protect from renal collecting system injury. *Journal of Urology*, **2005**, 174, 350-2	2.5	31
248	Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis. *BJU International*, **2016**, 117, E87-94	5.6	31
247	A Multi-Institutional Comparison of Clinicopathological Characteristics and Oncologic Outcomes of Upper Tract Urothelial Carcinoma in China and the United States. *Journal of Urology*, **2017**, 197, 1208-1213	2.5	30
246	Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. *BJU International*, **2014**, 114, 56-61	5.6	30
245	Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. *Journal of Urology*, **2014**, 191, 28-34	2.5	30
244	Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature. *European Urology*, **2020**, 78, 209-220	10.2	29
243	The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. *Cancer Journal (Sudbury, Mass)*, **2008**, 14, 308-14	2.2	29
242	Multi-institutional validation of the predictive value of Ki-67 in patients with high grade urothelial carcinoma of the upper urinary tract. *Journal of Urology*, **2015**, 193, 1486-93	2.5	28
241	Discordance between Ureteroscopic Biopsy and Final Pathology for Upper Tract Urothelial Carcinoma. *Journal of Urology*, **2018**, 199, 1440-1445	2.5	28
240	Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. *Urology*, **2009**, 73, 337-41	1.6	28
239	Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. *World Journal of Urology*, **2017**, 35, 355-365	4	27
238	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. *World Journal of Urology*, **2013**, 31, 5-11	4	27
237	Association of distance to treatment facility on quality and survival outcomes after radical cystectomy for bladder cancer. *Urology*, **2015**, 85, 876-82	1.6	26
236	The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. *BJU International*, **2015**, 116, 72-8	5.6	26
235	Prognostic effect of urinary bladder carcinoma in situ on clinical outcome of subsequent upper tract urothelial carcinoma. *Urology*, **2011**, 77, 861-6	1.6	26
234	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. *World Journal of Urology*, **2017**, 35, 121-130	4	25
233	Reconstruction of Large Perineal and Pelvic Wounds Using Gracilis Muscle Flaps. *Annals of Surgical Oncology*, **2015**, 22, 3738-44	3.1	25
232	Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprahepatic caval tumor thrombus. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 388.e1-9	2.8	25

231	Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 604.e9-604.e17	2.8	25
230	Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. *Journal of Urology*, **2017**, 197, 287-295	2.5	25
229	Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. *European Urology Oncology*, **2019**, 2, 397-404	6.7	25
228	Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. *International Journal of Radiation Oncology Biology Physics*, **2019**, 105, 367-375	4	24
227	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. *Clinical Genitourinary Cancer*, **2016**, 14, e585-e594	3.3	24
226	Effect of testicular germ cell tumor therapy on renal function. *Urology*, **2012**, 80, 641-8	1.6	24
225	Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. *Journal of Urology*, **2017**, 197, 580-589	2.5	23
224	Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology?. *Journal of Urology*, **2014**, 191, 926-31	2.5	23
223	Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. *Journal of Urology*, **2020**, 203, 1101-1108	2.5	23
222	Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: results of a current series and a review of the literature. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 54.e19-26	2.8	22
221	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. *BJU International*, **2013**, 112, 623-37	5.6	22
220	Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. *European Urology*, **2014**, 66, 379-85	10.2	21
219	Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway. *Clinical Cancer Research*, **2008** , 14, 5722-30	12.9	21
218	Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection. *European Urology*, **2020**, 77, 290-292	10.2	21
217	Preoperative multiplex nomogram for prediction of high-risk nonorgan-confined upper-tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 292.e1-292.e9	2.8	21
216	International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. *European Urology*, **2011**, 60, 673-83	10.2	20
215	Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. *Oncotarget*, **2016**, 7, 31508-19	3.3	20
214	Multi-disciplinary surgical approach to the management of patients with renal cell carcinoma with venous tumor thrombus: 15-year experience and lessons learned. *BMC Urology*, **2016**, 16, 43	2.2	20

213	Tumour and patient factors in renal cell carcinoma-towards personalized therapy. *Nature Reviews Urology*, **2015**, 12, 253-62	5.5	19
212	Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 167.e9-16	2.8	19
211	Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 268.e1-7	2.8	19
210	Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival. *Urologic Oncology: Seminars and Original Investigations*, **2014**, 32, 30.e23-8	2.8	19
209	Dysregulation of Ecatenin is an independent predictor of oncologic outcomes in patients with clear cell renal cell carcinoma. *Journal of Urology*, **2014**, 191, 1671-7	2.5	19
208	Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. *Cancer*, **2015**, 121, 43-50	6.4	18
207	Prognostic role of cell cycle and proliferative biomarkers in patients with clear cell renal cell carcinoma. *Journal of Urology*, **2013**, 190, 1662-7	2.5	18
206	Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 924-931	2.8	17
205	Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma. *Urology*, **2014**, 84, 1134-40	1.6	17
204	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). *World Journal of Urology*, **2017**, 35, 251-259	4	16
203	Preoperative nomogram to predict the likelihood of complications after radical nephroureterectomy. *BJU International*, **2017**, 119, 268-275	5.6	16
202	Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. *World Journal of Urology*, **2014**, 32, 615-22	4	16
201	Risk stratification of pubertal children and postpubertal adolescents with clinical stage I testicular nonseminomatous germ cell tumors. *Journal of Urology*, **2014**, 191, 1485-90	2.5	16
200	Cytoreductive nephrectomy in metastatic renal cell carcinoma. *Current Opinion in Urology*, **2008**, 18, 474-80	2.8	16
199	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. *World Journal of Urology*, **2017**, 35, 113-120	4	15
198	Predictive Nomogram for Recurrence following Surgery for Nonmetastatic Renal Cell Cancer with Tumor Thrombus. *Journal of Urology*, **2017**, 198, 810-816	2.5	15
197	Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. *World Journal of Urology*, **2015**, 33, 1165-71	4	15
196	Multi-institutional Evaluation of Upper Urinary Tract Biopsy Using Backloaded Cup Biopsy Forceps, a Nitinol Basket, and Standard Cup Biopsy Forceps. *Urology*, **2018**, 117, 89-94	1.6	15

195	Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. *European Urology*, **2012**, 62, e27-9	10.2	15
194	Assessment of hematuria. *Medical Clinics of North America*, **2011**, 95, 153-9	7	15
193	The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. *Journal of Endourology*, **2011**, 25, 775-9	2.7	15
192	Effect of warmed, humidified insufflation gas and anti-inflammatory agents on cytokine response to laparoscopic nephrectomy: porcine model. *Journal of Urology*, **2005**, 174, 1452-6	2.5	15
191	What is the role of nephrectomy following complete response to checkpoint inhibitors?. *Urology Case Reports*, **2018**, 18, 60-63	0.5	15
190	Statin Use and Serum Lipid Levels Are Associated With Survival Outcomes After Surgery for Renal Cell Carcinoma. *Urology*, **2015**, 86, 1146-52	1.6	14
189	Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small renal masses. *Urologic Oncology: Seminars and Original Investigations* , **2014**, 32, 37.e17-23	2.8	14
188	Elevated activated partial thromboplastin time during administration of first-generation adenoviral vectors for gene therapy for prostate cancer: identification of lupus anticoagulants. *Urology*, **2005**, 66, 830-4	1.6	14
187	Prognostic value of tissue-based biomarker signature in clear cell renal cell carcinoma. *BJU International*, **2017**, 119, 741-747	5.6	13
186	Usage and survival implications of surgical staging of inguinal lymph nodes in intermediate- to high-risk, clinical localized penile cancer: A propensity-score matched analysis. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 159.e7-159.e17	2.8	13
185	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. *Urology*, **2016**, 94, 314.e1-7	1.6	13
184	The role of systemic chemotherapy in management of upper tract urothelial cancer. *Current Urology Reports*, **2013**, 14, 94-101	2.9	13
183	Tissue-based biomarkers in prostate cancer. *Expert Review of Precision Medicine and Drug Development*, **2017**, 2, 249-260	1.6	13
182	Penile cancer: management of regional lymphatic drainage. *Urologic Clinics of North America*, **2010**, 37, 411-9	2.9	13
181	Application of novel hemostatic agent during laparoscopic partial nephrectomy. *Journal of Urology*, **2005**, 174, 761-4	2.5	13
180	The Adverse Survival Implications of Bland Thrombus in Renal Cell Carcinoma With Venous Tumor Thrombus. *Urology*, **2018**, 115, 119-124	1.6	12
179	Differences at Presentation and Treatment of Testicular Cancer in Hispanic Men: Institutional and National Hospital-based Analyses. *Urology*, **2018**, 112, 103-111	1.6	12
178	Current advances in BCG-unresponsive non-muscle invasive bladder cancer. *Expert Opinion on Investigational Drugs*, **2019**, 28, 757-770	5.9	12

177	Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 758-764	2.8	12
176	Pre-surgical targeted molecular therapy in renal cell carcinoma. *BJU International*, **2009**, 103, 150-3	5.6	12
175	Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy--results from a multicenter study. *European Urology*, **2008**, 54, 961-3	10.2	12
174	Preoperative predictors of nonorgan-confined disease in upper-tract urothelial carcinoma differ between China and the United States. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 88.e11-88.e18	2.8	12
173	Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. *Canadian Journal of Urology*, **2015**, 22, 7865-75	0.8	12
172	Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. *BJU International*, **2017**, 119, 234-238	5.6	11
171	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 53-64	2.8	11
170	Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. *Cancer Biology and Therapy*, **2015**, 16, 657-61	4.6	11
169	Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy. *European Urology Oncology*, **2019**, 2, 691-698	6.7	11
168	Multiple vesical calculi and complete vaginal vault prolapse. *American Journal of Obstetrics and Gynecology*, **2003**, 189, 884-5	6.4	11
167	Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type. *EBioMedicine*, **2020**, 51, 102526	8.8	11
166	Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. *BJU International*, **2016**, 118, 243-9	5.6	11
165	Prognostic serum markers in patients with high-grade upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2016**, 34, 418.e9-418.e16	2.8	11
164	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 495.e15-22	2.8	10
163	The Usefulness of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance. *Journal of Urology*, **2016**, 196, 321-6	2.5	10
162	LBA26 PHASE II TRIAL OF NEOADJUVANT CHEMOTHERAPY FOLLOWED BY EXTIRPATIVE SURGERY FOR PATIENTS WITH HIGH GRADE UPPER TRACT UROTHELIAL CARCINOMA (HG UTUC): RESULTS FROM ECOG-ACRIN 8141. *Journal of Urology*, **2018**, 199,	2.5	10
161	Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma: Preliminary Experience. *Clinical Genitourinary Cancer*, **2021**, 19, 12-21.e1	3.3	10
160	Need for upper urinary tract stenting in cases of ureteral orifice injury during laser enucleation of the prostate. *International Urology and Nephrology*, **2018**, 50, 2173-2177	2.3	10

159	Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. *Clinical Genitourinary Cancer*, **2018**, 16, e903-e908	3.3	9
158	Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy. *European Urology*, **2012**, 62, e25-6	10.2	9
157	Risk prediction in the management of small renal masses. *Current Opinion in Urology*, **2012**, 22, 347-52	2.8	9
156	Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. *Journal of Urology*, **2021**, 205, 137-144	2.5	9
155	The Rho GTPase signalling pathway in urothelial carcinoma. *Nature Reviews Urology*, **2018**, 15, 83-91	5.5	9
154	TALL score for prediction of oncological outcomes after radical nephroureterectomy for high-grade upper tract urothelial carcinoma. *World Journal of Urology*, **2015**, 33, 1965-72	4	8
153	Active Surveillance for Intermediate-Risk Prostate Cancer: Systematic Review and Meta-analysis of Current Protocols and Outcomes. *Clinical Genitourinary Cancer*, **2020**, 18, e739-e753	3.3	8
152	Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 602.e11-602.e19	2.8	8
151	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. *OncoTargets and Therapy*, **2017**, 10, 1487-1502	4.4	8
150	Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma. *Urologic Clinics of North America*, **2016**, 43, 105-18	2.9	8
149	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. *World Journal of Urology*, **2017**, 35, 1073-1080	4	8
148	Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy?. *International Braz J Urol: Official Journal of the Brazilian Society of Urology*, **2013**, 39, 614-21	2	8
147	The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. *European Urology Focus*, **2020**, 6, 104-111	5.1	8
146	Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study. *Clinical Genitourinary Cancer*, **2018**, 16, e1221-e1235	3.3	8
145	Therapeutic strategies for upper tract urothelial carcinoma. *Expert Review of Anticancer Therapy*, **2018**, 18, 765-774	3.5	8
144	Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes. *European Urology Oncology*, **2018**, 1, 242-251	6.7	8
143	Upper tract urothelial carcinoma: special considerations. *Clinical Advances in Hematology and Oncology*, **2016**, 14, 101-9	0.6	8
142	Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma. *European Radiology*, **2018**, 28, 124-132	8	7

141	Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *World Journal of Urology*, **2016**, 34, 1411-9	4	7
140	Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. *Clinical Genitourinary Cancer*, **2017**, 15, e1039-e1045	3.3	7
139	In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2010**, 10, 837-42	3.5	7
138	Role of cytoreductive nephrectomy in renal cell carcinoma. *Future Oncology*, **2009**, 5, 859-69	3.6	7
137	Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype With Additional Insights From a Case With MTOR Mutation and Concomitant Chromosome 1 Loss. *Advances in Anatomic Pathology*, **2021**, 28, 251-257	5.1	7
136	Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy. *Urologic Oncology: Seminars and Original Investigations*, **2019**, 37, 57-62	2.8	7
135	Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 409-421	2.8	7
134	Molecular profile of urothelial carcinoma of the upper urinary tract: are pelvicalyceal and ureteral tumors different?. *World Journal of Urology*, **2016**, 34, 105-12	4	6
133	Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: preliminary results. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 18.e21-18.e26	2.8	6
132	Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. *Clinical Proteomics*, **2009**, 5, 37-45	5	6
131	Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. *Current Oncology Reports*, **2008**, 10, 253-8	6.3	6
130	Vaginal vault fixation and prevention of enterocele recurrence by high midline levator myorraphy: physical examination and questionnaire-based follow-up. *European Urology*, **2001**, 40, 648-51	10.2	6
129	Single stage Xi robotic radical nephroureterectomy for upper tract urothelial carcinoma: surgical technique and outcomes. *Minerva Urology and Nephrology*, **2021**,	2.3	6
128	Oncologic outcomes of radical nephroureterectomy (RNU). *Translational Andrology and Urology*, **2020**, 9, 1841-1852	2.3	6
127	Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital. *Cancer*, **2020**, 126, 4362-4370	6.4	6
126	Serum Small RNA Sequencing and miR-375 Assay Do Not Identify the Presence of Pure Teratoma at Postchemotherapy Retroperitoneal Lymph Node Dissection. *European Urology Open Science*, **2021**, 26, 83-87	0.9	6
125	Comparing Changes in Renal Function After Radical Surgery for Upper Tract Urothelial Carcinoma and Renal Cell Carcinoma. *Urology*, **2016**, 96, 44-53	1.6	6
124	Robotic Nephroureterectomy Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically. *Journal of Endourology*, **2021**, 35, 312-318	2.7	6

123	Risk Factors for Intravesical Recurrence after Minimally Invasive Nephroureterectomy for Upper Tract Urothelial Cancer (ROBUUST Collaboration). *Journal of Urology*, **2021**, 206, 568-576	2.5	6
122	Metastatic Melanoma to the Bladder: Case Report and Review of the Literature. *Urology Case Reports*, **2017**, 11, 33-36	0.5	5
121	Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma. *BMC Urology*, **2015**, 15, 24	2.2	5
120	Perioperative outcomes and cost of robotic vs open simple prostatectomy in the modern robotic era: results from the National Inpatient Sample. *BJU International*, **2021**, 128, 168-177	5.6	5
119	Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 601.e17-601.e24	2.8	5
118	Imaging for Screening and Surveillance of Patients with Hereditary Forms of Renal Cell Carcinoma. *Current Urology Reports*, **2018**, 19, 82	2.9	5
117	Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *European Urology*, **2013**, 63, 1134-5	10.2	5
116	Outcomes for patients with pT0 disease after radical nephroureterectomy for upper-tract urothelial carcinoma. *BJU International*, **2009**, 103, 3-4	5.6	5
115	Safety and feasibility of nephrectomy after receipt of immune checkpoint inhibitors for renal cell carcinoma.. *Journal of Clinical Oncology*, **2019**, 37, 619-619	2.2	5
114	Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. *BJU International*, **2021**, 128, 57-64	5.6	5
113	SPARC is a key mediator of TGF-□nduced renal cancer metastasis. *Journal of Cellular Physiology*, **2021**, 236, 1926-1938	7	5
112	Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. *Cancer Immunology, Immunotherapy*, **2021**, 70, 2641-2650	7.4	5
111	Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 933.e7-933.e12	2.8	4
110	Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 737.e11-737.e16	2.8	4
109	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. *World Journal of Urology*, **2016**, 34, 1155-61	4	4
108	The use of preoperative targeted molecular therapy to allow nephron sparing for T1b tumors. *Current Opinion in Urology*, **2013**, 23, 411-7	2.8	4
107	A renal cell carcinoma tumorgraft platform to advance precision medicine. *Cell Reports*, **2021**, 37, 110055	10.6	4
106	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. *World Journal of Urology*, **2019**, 37, 2419-2427	4	4

105	Advancements in the clinical management of upper tract urothelial carcinoma. *Expert Review of Anticancer Therapy*, **2019**, 19, 1051-1060	3.5	4
104	Is cytoreductive nephrectomy relevant in the immunotherapy era?. *Current Opinion in Urology*, **2019**, 29, 526-530	2.8	4
103	Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer. *Clinical Genitourinary Cancer*, **2019**, 17, e184-e186	3.3	4
102	Pathologic Predictors of Survival During Lymph Node Dissection for Metastatic Renal-Cell Carcinoma: Results From a Multicenter Collaboration. *Clinical Genitourinary Cancer*, **2018**, 16, e443-e450	3.3	4
101	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2019**, 39, 262-275	7.1	3
100	Safety and Short-Term Oncological Outcomes of Thulium Fiber Laser En Bloc Resection of Non-Muscle-Invasive Bladder Cancer: A Prospective Non-Randomized Phase II Trial. *Bladder Cancer*, **2020**, 6, 201-210	1	3
99	Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes?. *Journal of Adolescent and Young Adult Oncology*, **2016**, 5, 248-53	2.2	3
98	Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2013**, 31, 676-81	2.8	3
97	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. *Journal of Urology*, **2017**, 198, 1269-1277	2.5	3
96	Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary bladder: can post-induction random bladder biopsies be avoided?. *Cytopathology*, **2014**, 25, 108-11	1.3	3
95	Prognostic markers in renal cell carcinoma: A focus on the Qmammalian target of rapamycinQ pathway. *Arab Journal of Urology Arab Association of Urology*, **2012**, 10, 110-7	1.7	3
94	Prognostic Factors for Contralateral Recurrence of Upper Tract Urothelial Carcinoma after Nephroureterectomy: A Large Multiregional Study. *Cancers*, **2021**, 13,	6.6	3
93	Determinants of renal cell carcinoma invasion and metastatic competence. *Nature Communications*, **2021**, 12, 5760	17.4	3
92	Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. *World Journal of Urology*, **2021**, 39, 2567-2577	4	3
91	Neoadjuvant SABR for Renal Cell Carcinoma Inferior Vena Cava Tumor Thrombus-Safety Lead-in Results of a Phase 2 Trial. *International Journal of Radiation Oncology Biology Physics*, **2021**, 110, 1135-1142	4	3
90	Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle. *European Urology Oncology*, **2020**, 3, 198-206	6.7	3
89	Prospective evaluation of blue-light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer. *BJU International*, **2021**, 127, 108-113	5.6	3
88	The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: A systematic review and meta-analysis. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 15-33	2.8	3

87	Value of tumour-infiltrating immune cells in predicting response to intravesical BCG in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis. *BJU International*, **2021**, 127, 617-625	5.6	3
86	Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Translational Andrology and Urology*, **2021**, 10, 609-619	2.3	3
85	Molecularly-driven precision medicine for advanced bladder cancer. *World Journal of Urology*, **2018**, 36, 1749-1757	4	3
84	Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform. *Clinical Cancer Research*, **2021**, 27, 4794-4806	12.9	3
83	Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance. *Journal of Urology*, **2017**, 198, 1021-1026	2.5	2
82	Stereotactic Ablative Radiotherapy (SAbR) in the Setting of Metastatic Nonseminomatous Germ Cell Tumor of Testis. *Clinical Genitourinary Cancer*, **2019**, 17, e768-e771	3.3	2
81	Predicting recurrence in patients with localised renal cell carcinoma after nephrectomy. *Lancet Oncology, The*, **2019**, 20, 473-475	21.7	2
80	Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence After Nephrectomy for Renal Cell Carcinoma. *Urology*, **2020**, 145, 159-165	1.6	2
79	Validation of Hyponatremia as a Prognostic Predictor in Multiregional Upper Tract Urothelial Carcinoma. *Journal of Clinical Medicine*, **2020**, 9,	5.1	2
78	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2018**, 36, 343.e1-343.e8	2.8	2
77	Stereotactic Body Radiation Therapy for Renal Cell Carcinoma with Inferior Vena Cava Thrombus Initial Experience Report and Literature Review. *Kidney Cancer*, **2019**, 3, 71-77	0.6	2
76	Increased use of antihypertensive medications after partial nephrectomy vs. radical nephrectomy. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 660.e17-660.e25	2.8	2
75	Urinary retention after tension-free vaginal tape procedure: from incision to excision...to complete urethrolysis. *Urology*, **2004**, 64, 590	1.6	2
74	Prognostic effect of preoperative systemic immune-inflammation index in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Minerva Urology and Nephrology*, **2021**,	2.3	2
73	Robotic vs laparoscopic nephroureterectomy for upper tract urothelial carcinoma: a multicenter propensity-score matched pair "tetrafecta" analysis (ROBUUST collaborative group).. *Journal of Endourology*, **2022**,	2.7	2
72	Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma. *Clinical Cancer Research*, **2021**,	12.9	2
71	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 496-505	2.8	2
70	Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 936.e7-936.e14	2.8	2

69	Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 736.e11-736.e18	2.8	2
68	The Significance of Preoperative Serum Sodium and Hemoglobin in Outcomes of Upper Tract Urothelial Carcinoma: Multi-Center Analysis Between China and the United States. *Cancer Management and Research*, **2020**, 12, 9825-9836	3.6	2
67	Population-based analysis of cost and peri-operative outcomes between open and robotic primary retroperitoneal lymph node dissection for germ cell tumors. *World Journal of Urology*, **2021**, 39, 1977-1984	4	2
66	Metastasis-directed radiation therapy after radical cystectomy for bladder cancer. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 790.e1-790.e7	2.8	2
65	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. *European Urology Focus*, **2019**, 5, 97-103	5.1	2
64	A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group). *European Urology Focus*, **2021**,	5.1	2
63	Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma. *Advances in Radiation Oncology*, **2021**, 6, 100692	3.3	2
62	Preoperative hydronephrosis is associated with less decline in renal function after radical nephroureterectomy for upper tract urothelial carcinoma. *Canadian Journal of Urology*, **2016**, 23, 8334-41	0.8	2
61	The use of cytoreductive nephrectomy in patients with renal cell carcinoma. *Expert Review of Anticancer Therapy*, **2019**, 19, 405-411	3.5	1
60	Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical	10.2	1
59	MP77-09 FEASIBILITY OF OBTAINING BIOMARKER PROFILES FROM ENDOSCOPIC BIOPSY SPECIMENS IN UPPER TRACT UROTHELIAL CARCINOMA: PRELIMINARY RESULTS. *Journal of Urology*, **2014**, 191,	2.5	1
58	Rapid progression of a germ cell tumor encasing the inferior vena cava and aorta following a radical orchiectomy. *Rare Tumors*, **2013**, 5, 79-82	1.1	1
57	Utilization and survival implications of a delayed approach to targeted therapy for metastatic renal cell carcinoma: A nationwide cancer registry study.. *Journal of Clinical Oncology*, **2018**, 36, 586-586	2.2	1
56	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. *Urologic Oncology: Seminars and Original Investigations*, **2020**, 38, 685.e17-685.e25	2.8	1
55	Editorial Comment. *Journal of Urology*, **2019**, 201, 76	2.5	1
54	Incidence and preoperative predictors for major complications following radical nephroureterectomy. *Translational Andrology and Urology*, **2020**, 9, 1786-1793	2.3	1
53	Safety, Efficacy, and Impact on Quality of Life of Palliative Robotic Cystectomy for Advanced Prostate Cancer. *Clinical Genitourinary Cancer*, **2021**, 19, e129-e134	3.3	1
52	A Review Leveraging a Rare and Unusual Case of Basal Cell Carcinoma of the Prostate. *Case Reports in Pathology*, **2021**, 2021, 5520581	0.9	1

51	Demographic Factors Associated With Non-Guideline-Based Treatment of Kidney Cancer in the United States. *JAMA Network Open*, **2021**, 4, e2112813	10.4	1
50	Disparities in Pre-Orchiectomy Sperm Cryopreservation Among Testicular Cancer Patients at a Public Safety Net Hospital and a Private Tertiary Care Center. *Urology*, **2021**,	1.6	1
49	Transesophageal Echocardiography Imaging of the Inferior Vena Cava and Hepatic Vein Masses. *A&A Practice*, **2019**, 12, 295-297	0.8	1
48	Sex differences in upper tract urothelial carcinomas. *Current Opinion in Urology*, **2019**, 29, 256-260	2.8	1
47	Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. *World Journal of Urology*, **2019**, 37, 1631-1637	4	1
46	Interethnic differences in the impact of body mass index on upper tract urothelial carcinoma following radical nephroureterectomy. *World Journal of Urology*, **2021**, 39, 491-500	4	1
45	Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. *Japanese Journal of Clinical Oncology*, **2021**, 51, 1149-1157	2.8	1
44	Re: Alison Birtle, Mark Johnson, John Chester, et al. Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. Lancet 2020;395:1268-77: A New Standard for a Rare Disease? Optimizing the Timing of Chemotherapy for Upper Tract Urothelial Carcinoma. *European Urology*, **2021**, 79, e28	10.2	1
43	Outcomes of Lymph Node Dissection in Nephroureterectomy in the Treatment of Upper Tract Urothelial Carcinoma: Analysis of the ROBUUST Registry.. *Journal of Urology*, **2022**, 101097JU0000000000002690	2.5	1
42	The early impact of medicaid expansion on urologic malignancies in the United States. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 40, 103.e1-103.e1	2.8	0
41	Prophylaxis Against Thromboembolic Events During Chemotherapy for Germ Cell Cancer. *Frontiers in Oncology*, **2021**, 11, 724682	5.3	0
40	Validation of testicular germ cell tumor staging in nationwide cancer registries. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 838.e1-838.e6	2.8	0
39	Predictive capacity of miRNA-375 in identifying teratoma in post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. *Journal of Clinical Oncology*, **2020**, 38, 416-416	2.2	0
38	Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer. *European Urology Open Science*, **2020**, 19, 16-19	0.9	0
37	Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.. *Journal of Clinical Oncology*, **2021**, 39, 311-311	2.2	0
36	Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. *Urologic Oncology: Seminars and Original Investigations*, **2021**, 39, 788.e15-788.e21	2.8	0
35	Clinical outcomes of a cohort of patients with bulky, clinically node-positive bladder cancer undergoing radical cystectomy in the contemporary era. *Canadian Urological Association Journal*, **2021**, 15, E286-E289	1.2	
34	The Changing Landscape of Upper Tract Urothelial Carcinoma Management. *Urology*, **2020**, 145, 316-318	1.6	

33	Editorial Comment from Dr Haddad and Dr Margulis to Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: Subanalysis of the multi-institutional national database of the Japanese Urological Association. *International Journal of Urology*, **2015**, 22, 1022	2.3
32	Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: What Percentage of Patients Qualifies for Bladder Preservation Protocols?. *Current Urology*, **2007**, 1, 24-27	1.7
31	Serum microRNA-371a-3p levels to predict viable germ cell tumor in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection.. *Journal of Clinical Oncology*, **2020**, 38, 417-417	2.2
30	Reply by Authors. *Journal of Urology*, **2020**, 203, 697-698	2.5
29	Gossypiboma manifesting as urachal mass. *Reviews in Urology*, **2016**, 18, 239-241	1
28	IS THERE A ROLE FOR RADIATION FOR PRIMARY KIDNEY TUMORS? **2019**, 24, 4	
27	Differences between Upper Tract Urothelial Carcinoma and Bladder Cancer **2021**, 26, 15-16	
26	Performance characteristics of F-fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection.. *Canadian Urological Association Journal*, **2022**, 16, E167-E172	1.2
25	Editorial Comment. *Journal of Urology*, **2020**, 204, 536	2.5
24	Size-focality-invasion in upper tract urothelial carcinoma (SFI-UTUC): A novel imaging-based score to predict survival outcomes.. *Journal of Clinical Oncology*, **2018**, 36, 475-475	2.2
23	Utility of lymph node dissection for clinical node negative upper tract urothelial cell carcinoma: A multicenter study.. *Journal of Clinical Oncology*, **2018**, 36, 474-474	2.2
22	Cytoreductive Nephrectomy and Metastasectomy for Renal Cell Carcinoma **2019**, 299-311	
21	Assessment of intratumor heterogeneity using imaging texture features in clear cell renal cell carcinoma.. *Journal of Clinical Oncology*, **2019**, 37, 663-663	2.2
20	Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients.. *Journal of Clinical Oncology*, **2019**, 37, 651-651	2.2
19	Outcomes of stereotactic ablative radiotherapy for extra-cranial oligo-metastatic renal cell cancer.. *Journal of Clinical Oncology*, **2019**, 37, 599-599	2.2
18	The role of architectural patterns and cytologic features in the prognosis of clear cell renal cell carcinoma.. *Journal of Clinical Oncology*, **2019**, 37, 632-632	2.2
17	Editorial Comment. *Journal of Urology*, **2019**, 201, 1086	2.5
16	Overcoming sociodemographic factors in the care of testicular cancer patients at a safety net hospital.. *Journal of Clinical Oncology*, **2020**, 38, 398-398	2.2

15	Performance characteristics of 18F-Fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection.. *Journal of Clinical Oncology*, **2020**, 38, 390-390	2.2
14	Effect of increasing Medicaid coverage in Medicaid expansion states on stage at presentation for urologic malignancies.. *Journal of Clinical Oncology*, **2020**, 38, 400-400	2.2
13	Conservative Management of Low-Risk UTUC **2015**, 119-130	
12	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).. *Journal of Clinical Oncology*, **2012** , 30, TPS4678-TPS4678	2.2
11	EDITORIAL COMMENT. *Urology*, **2019**, 129, 85	1.6
10	Sarcopenia prior to and following chemotherapy to predict morbidity in patients undergoing post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND).. *Journal of Clinical Oncology*, **2021**, 39, 381-381	2.2
9	Nephroureterectomy for Upper Tract Urothelial Carcinoma: Indications and Technique **2021**, 439-446	
8	Optimizing oncologic outcomes in upper tract urothelial carcinoma. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2016**, 68, 372-80	4.4
7	Urothelial carcinoma of the upper urinary tracts: current knowledge and future perspectives. *Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology*, **2016**, 68, 348-9	4.4
6	Evaluation of a risk-adapted strategy in the primary surgical management of clinical stage IIA testicular cancer.. *Journal of Clinical Oncology*, **2022**, 40, 414-414	2.2
5	Molecular analysis of primary testicular germ cell tumor and matched metastatic teratomas.. *Journal of Clinical Oncology*, **2022**, 40, 425-425	2.2
4	Evaluating the discriminatory capacity of miR-371A-3P in the context of pure seminomatous testicular cancer metastases.. *Journal of Clinical Oncology*, **2022**, 40, 424-424	2.2
3	Actionable genomic landscapes from a real-world cohort of localized urothelial carcinoma patients.. *Journal of Clinical Oncology*, **2022**, 40, 525-525	2.2
2	Role of preoperative albumin in predicting risk of postoperative complications in patients undergoing post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND).. *Journal of Clinical Oncology*, **2022**, 40, 416-416	2.2
1	Routine Overnight Vital Signs Are Rarely Associated with Major Clinical Events in Patients Undergoing Radical Cystectomy: A Retrospective Cohort Study. *Urology Practice*, **2022**, 9, 150-157	0.8